Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Brain Res ; 1595: 19-28, 2015 Jan 21.
Article in English | MEDLINE | ID: mdl-25446001

ABSTRACT

Ligustilide (LIG) is a principal active ingredient of traditional Chinese medicine, Radix Angelica sinensis, which has versatile pharmacological activities including neuroprotection. Previous studies have demonstrated that LIG has beneficial effects on cognition deficits associated with cerebral damage or neurodegenerative disorders. In present study, we investigated the neuroprotective effect of LIG on cognitive impairment and neurotoxicity in the brain of aging mouse induced by d-galactose (d-gal). The aging model mice were induced by subcutaneous (S.C.) injection of d-gal once daily for 8 weeks and LIG (80 mg/kg) was simultaneously administered orally. The Morris water maze (MWM) test was used to assess the spatial learning and memory abilities. The activity of Na(+)-K(+)-ATPase and the content of lipid peroxidation product malondialdehyde (MDA) in brain were examined. The levels of glial fibrillary acidic protein (GFAP), growth-associated protein GAP-43, and cleaved caspase-3 in brain were also determined by immunohistochemistry. The MWM test showed that LIG administration markedly improved behavioral performance of d-gal treated mice. This action could be partly explained by the results that LIG reduced the level of MDA as well as increased the activity of Na(+)-K(+)-ATPase in the brain of d-gal induced aging mice. Moreover, LIG significantly raised the expression of GAP-43 and reduced cleaved caspase-3 and GFAP levels in the brain of d-gal treated mice. These results demonstrated that LIG improves d-gal-induced cognitive dysfunction and brain toxicity, which suggests that LIG may be developed as a new medicine for the treatment of aged-related conditions.


Subject(s)
4-Butyrolactone/analogs & derivatives , Cognition Disorders/etiology , Cognition Disorders/prevention & control , Neuroprotective Agents/therapeutic use , Neurotoxicity Syndromes/complications , 4-Butyrolactone/therapeutic use , Aging/drug effects , Animals , Brain/drug effects , Brain/metabolism , GAP-43 Protein/metabolism , Galactose/toxicity , Gene Expression Regulation/drug effects , Glial Fibrillary Acidic Protein/metabolism , Male , Malondialdehyde/metabolism , Maze Learning/drug effects , Mice , Mice, Inbred ICR , Neurotoxicity Syndromes/etiology , Sodium-Potassium-Exchanging ATPase/metabolism , Statistics, Nonparametric
SELECTION OF CITATIONS
SEARCH DETAIL
...